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Background: Chronic non-cancer pain (CNCP) is a major health concern. Opioids may be a useful
treatment option, but their use still remains controversial given the significant risks and epidemic of
opioid addiction and abuse. There is limited data on whether opioid therapy is an effective treatment
option for chronic non-cancer pain.
Objective: To assess both physical and emotional dimensions of health for patients on opioid therapy
for CNCP by reviewing the 36-Item Short Form Health Survey (SF-36) .
Study Design: This study was a retrospective cohort review.
Setting: Outpatient pain clinic
Methods: We recruited 182 patients at the West Penn Pain Institute outpatient pain clinic: 94 patients
were recruited for the low-dose opioid group (5-30 morphine milligram equivalents [MME]) while 88
patients were recruited for the high-dose opioid group (> 90 MME). Each patient filled out the SF-36
survey used to assess both the physical and emotional dimensions of their health. We also analyzed
patients’ employment status, reasons for unemployment, pain diagnosis, side effects, and compliance
issues through the electronic medical record (EMR).
Results: Mean scores on General Health Perceptions for the low-dose and high-dose opioid groups were
50.3 ± 21.6 and 44.4 ± 21.9, respectively (P = .07). Though not reaching statistical significance, highdose patients had lower item scores, indicating a perception of poorer health. There were no significant
differences between the low-dose and high-dose opioid treatment groups on any of the mean scores
from the 8 domains of the SF-36.
There was a statistically significant association between opioid treatment group and working status,
noncompliance, and the self-reported number of side effects. Patients treated with high-dose opioids had
significantly higher rates of unemployment (85%) than did low-dose opioid patients (66%) (χ2[1] = 8.48, P
=.004; odds ratio [OR] = 2.89 [95% confidence interval (CI), 1.39-6.01]). Unemployed patients in the highdose treatment group were more likely to list disability as unemployment while retirement was the most
common response in the low-dose treatment group. Patients treated with high-dose opioids had significantly
higher rates of self-reported side effects (46%) than did low-dose opioid patients (21%) (χ2[1] = 12.02, P
=.001; OR = 3.08 [95% CI, 1.61-5.89]). Patients treated with high-dose opioids had significantly higher rates
of noncompliance (49%) than did low-dose opioid patients (33%) (χ2[1] = 4.75, P =.029; OR = 1.94 [95%
CI, 1.07-3.54]). Thus, the odds of a high-dose opioid patient being unemployed were 2.89 times greater than
the odds for a low-dose opioid patient; the odds of a high-dose opioid patient self-reporting side-effects were
3.08 times greater than the odds for a low-dose opioid patient; and the odds of a high-dose opioid patient
being noncompliant with their medications were 1.94 times greater than the odds for a low-dose opioid
patient.
Limitations: The observation al design prohibits drawing causal relationships, and entry criteria was
restricted.
Conclusions: These data suggest that patients receiving low-dose and high-dose opioid treatment do
not have significantly different quality-of-life outcomes. Future studies that incorporate longitudinal data
are necessary to examine the temporal relationship between quality of life and opioid therapy.
Key words: Chronic pain, chronic non-cancer pain, opioids, pain, quality of life, side effects,
noncompliance, unemployment
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C

hronic pain is defined as pain that persists
beyond the normal tissue healing time of 3
months. When chronic pain is not associated
with cancer or end-of-life care, it is often referred to as
“chronic non-cancer pain” (CNCP). CNCP is a prevalent
health problem and accounts for a large proportion of
health care expenditures. In addition, it is the leading
cause of disability and can have a major influence on
the patient in terms of quality of life, mental health,
relationships, and employment. Opioids are one of the
most potent analgesics available. They have a large role
in the surgical setting and acute pain, but their use as
a treatment option for chronic pain – specifically CNCP
– remains controversial given the significant risks and
given an epidemic of opioid addiction and abuse. There
is limited data about the long-term effectiveness of
opioids in regard to a patient’s physical and emotional
health, specifically their functional health, well-being,
psychometrically-based physical health, and mental
health. There are also concerns about opioid tolerance,
their side-effect profile, and anxiety over disapproval
by regulatory bodies. These concerns are heightened
for patients prescribed high doses of opioids. Despite
this, the use of opioids for chronic non-cancer pain
has increased substantially since the 1990s. High-dose
opioid therapy occurs in 2% to 3% of patients with
CNCP or low-back pain and among 8% of patients
prescribed chronic opioid therapy (1). There is limited
research evaluating the effectiveness of high-dose
opioid therapy and its consequences for patients with
CNCP, especially in comparison with low-dose opioid
treatment.
High-dose opioid use can also lead to hyperalgesia,
a form of central sensitization in which a patient’s pain
level increases in parallel with elevation of his or her
opioid use. A retrospective study looked at 23 patients
undergoing detoxification from high-dose opioids for
chronic pain. Of those 23 patients, 21 reported a significant decrease in pain score after detoxification, which
may provide some evidence for the phenomenon of
hyperalgesia (2). A similar phenomenon of pain reduction after discontinuation of opioid medications was
also examined by Sjogren et al. They reported 4 cases of
cancer patients who developed hyperalgesia while on
morphine. The hyperalgesia resolved after morphine
withdrawal or opioid substitution (3).
One of the major reasons why chronic dose opioid
therapy is controversial is concern about developing tolerance. This often occurs in patients maintained on opioids over a prolonged period. As a result, patients will
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need an increased dose of opioids in order to achieve
a level of pain alleviation comparable to that initially
achieved. For instance, a prospective cohort study by
Campbell et al found that patients taking higher-dose
opioids were more likely to have higher pain scores
than patient groups taking lower-dose opioids, which
may provide some explanation for the phenomenon of
tolerance. A prospective study by Chu et al found that
patients may have developed tolerance to morphine
only after one month of use (4).
Another major concern about high-dose opioid
therapy for CNCP is regarding aberrant drug behavior.
Morasco et al performed a retrospective cohort study to
compare patients on high-dose opioids and traditionaldose opioid therapy. Patients in the high-dose opioid
group were more likely to have more medical visits,
attempt an opioid taper, receive a urine drug screen,
and develop a pain goal than the traditional opioid
dose group (1). This may suggest that patients receiving
high-dose opioid therapy may be at less risk of aberrant drug behavior than originally thought. However,
a prospective cohort study by Campbell et al found
conflicting results; patients taking higher-dose opioids
were more likely to have aberrant drug behavior (5).
There is also concern that opioid use may lead to
a decline in a patients’ mental health and lead to functional impairment. A retrospective study by Huffman
et al found that patients weaned from opioid therapy
after one year showed improvement in depression and
anxiety and were less likely to be functionally impaired
(6). A randomized control study by Kidner et al showed
that patients taking higher dose of opioids were more
likely to not return to work, become unemployed, and
to be receiving social security disability insurance (7).
The current literature has suggested variable and
conflicting results regarding the social and functional
implications of chronic opioid therapy for CNCP. This
study aims to provide further research regarding the
effectiveness of high-dose opioid therapy and compare
it to low-dose opioids for CNCP.

Methods
Study Design and Setting
The Institutional Review Board (IRB) at Allegheny
Health Network provided approval for this study. We
did a retrospective cohort study of patients being
treated at the West Penn Pain Institute for chronic
non-cancer pain with opioids between June 2016 and
June 2018. The West Penn Institute is an outpatient
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pain clinic in Pittsburgh affiliated with the
teaching hospital of the Allegheny Health
Network. Patients are treated with a medical
team consisting of nurses, residents, fellows,
and attending physicians.

Eligibility Criteria
The study cohort consisted of patients
between the ages of 18 and 80 who had
been suffering from a pain condition for at
least 3 years. Patients were excluded if they
had a concurrent diagnosis of cancer, did not
speak or understand English, were deemed
to be noncompliant, or were receiving endof-life care. After they were deemed eligible
for the study, each patient’s current opioid
therapy was examined through the Pennsylvania Drug Monitoring Program (PDMP). The
PDMP is a statewide program that collects
information about controlled substance prescription drugs that are dispensed to patients
within the state and surrounding states. Patients were divided into 2 groups based on
daily oral morphine milligram equivalents
(MME). Patients were placed into the lowdose opioid group if their opioid usage was
between 5-30 MME; they were placed in the
high-dose opioid group if their opioid usage
was equal to or greater than 90 MME. Daily
oral MME doses for the opioids taken by the
cohort were estimated following review and
synthesis of a range of clinical guidelines (8).
Patients with MME between these 2 groups
were not included for the purpose of this
study. After obtaining written informed consent, patients were recruited into the study.

functional status, well-being, and “overall evaluation of health”
(10). The domains can also provide a summary of both physical
and emotional quality of life. It has been validated, is used widely
across medical disciplines, and can be self-administered by the patient with reliability. The SF-36 has been implemented to define
disease conditions, to determine the effect of treatment, and to
differentiate the effects of different treatments (11).
A single question is also included in the survey that gauges
perceived change in health from the prior year. Interpretation of
the SF-36 scores is based on the mean (average) scores of patients
(12). All items are scored on a scale of 0 to 100 so that a high score
defines a more favorable health state. Items that are left blank
(missing data) are not taken into account when calculating the
scale scores (8). Figure 1 shows the 8 domains of the SF-36 and the
percentage contribution of each domain to the survey.

Demographic Data
The following demographic data were obtained through
careful review of the patient’s electronic medical record (EMR):
age, body mass index (BMI), gender, pain diagnosis, complications, and side effects. In addition, employment status and reason for unemployment were obtained through interview of the
patient at the time of their visit of clinic.

Statistical Methods
Data analysis began with assessment of the normality of continuous variables using the Kolmogorov-Smirnov test. Continuous

Quality of Life Measures
Quality of life was measured through
the 36-Item Short Form Health Survey Instrument (SF-36) survey. All patients were given
the SF-36 at the time of visit to the clinic.
The SF-36 measures 8 health concepts (also
referred to as domains): physical functioning,
bodily pain, role limitations due to physical health problems, role limitations due to
personal or emotional problems, emotional
well-being, social functioning, energy/fatigue, and general health perceptions (9).
These domains measure 3 aspects of health –
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Fig. 1. Eight domains of the SF-36 and Percentage Contribution to the
Survey
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and normally distributed data are reported as means
and standard deviations; nonnormally distributed
data are reported as median with interquartile range
(IQR). Categorical variables are reported as counts and
percentages. The independent samples t test or MannWhitney test was used to compare continuous variables
between the low-dose and high-dose opioid treatment
groups. The chi-square test was used to compare categorical variables between groups. Odds ratios (OR) with
95% confidence intervals (CI) are reported when the
chi-square test was statistically significant. Cronbach’s
alpha was used to assess the reliability of the SF-36. A
value of P < .05 on 2-tailed testing was considered statistically significant. Statistical analyses were performed
using SPSS Version 24.0 (IBM Corporation, Armonk, NY).

Results
A total of 182 patients who received treatment
with opioids for the relief of non-cancer pain were
analyzed. The mean patient age was 59.3 ± 13.0 years
(range, 23-94 years) and 65.4% of the patients were
women. The median BMI was 30.2 kg/m2 (IQR = 8.4).
Patients were divided into groups based on their
opioid treatment dose. There was a slightly higher
proportion of patients receiving low-dose opioids compared with high-dose opioids (52% vs 48%). All patients
were given the SF-36 to complete posttreatment.
The 2 opioid treatment groups did not differ
significantly in the baseline characteristics of age (P
= .99), BMI (P = .15) or gender (P = .08); however, in
both treatment groups, patients were more likely to be
women (65.4%) than men (34.6%), and more women
were in the low-dose opioid treatment group (71.3%)
compared to the high-dose group (59.1%). The baseline
characteristics of the patients are reported in Table 1.
When the high-dose and low-dose opioid treatment groups were compared on 6 common diagnoses

(e.g., leg pain, leg + hip pain, hip pain (only), back pain,
neck + head pain, peripheral pain, and all other pain
not falling into the previous categories), the groups
did not differ significantly on the number of reported
diagnoses (P = .85).
Seventy-five percent of the study patients completed the SF-36; completion rates did not differ significantly between the low-dose and high-dose opioid
treatment groups (73% vs. 76%, P = .67). Although
completion of the SF-36 was not significantly related to
the baseline characteristics of opioid dosage, gender (P
= .27), or BMI (P = .88), there was a significant difference
in completion rates of the SF-36 by patient age. Patients
who did not complete the form were significantly older
than patients who did complete the form (62.2 ± 13.5
years [n = 46] vs 58.2 ± 12.7 years [n = 136]; t[180] =
-1.998, P = .047 [95% CI, -8.765 to -0.55]).
There was a statistically significant association
between opioid treatment group and working status,
noncompliance, and the self-reported number of side
effects (Table 2). Patients treated with high-dose opioids
had significantly higher rates of unemployment (85%)
than did low-dose opioid patients (66%) (χ2[1] = 8.48,
P =.004; OR = 2.89 [95% CI, 1.39-6.01]). Patients treated
with high-dose opioids had significantly higher rates of
self-reported side effects (46%) than did low-dose opioid
patients (21%) (χ2[1] = 12.02, P = .001; OR = 3.08 [95% CI,
1.61-5.89]). Patients treated with high-dose opioids had
significantly higher rates of noncompliance (49%) than
did low-dose opioid patients (33%) (χ2[1] = 4.75, P =.029;
OR = 1.94 [95% CI, 1.07-3.54]). Thus, we can say that the
odds of a high-dose opioid patient being unemployed
were 2.89 times greater than the odds for a low-dose
opioid patient; the odds of a high-dose opioid patient
self-reporting side-effects were 3.08 times greater than
the odds for a low-dose opioid patient; and the odds of a
high-dose opioid patient being noncompliant with their

Table 1. Baseline characteristics of patients treated with low- vs high-dose opioids for non-cancer pain (n = 182)*.

Low-Dose
Opioid Group (n = 94)

High-Dose
Opioid Group (n = 88)

Age in yrs, mean ± SD

59.3 ± 13.1

59.3 ± 13.0

.99

BMI kg/m2, median (IQR)

30.6 (9.9)

29.9 (8.0)

.15

Men

27 (28.7)

36 (40.9)

Women

67 (71.3)

52 (59.1)

Variable

P Value

Gender, n (%)
08

Abbreviations: BMI, body mass index; IQR, interquartile range; SD, standard deviation; SF-36, 36-Item Short Form Health Survey.
* Data are presented as mean ± SD, median (25%-75% IQR), or count (percentage).
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Table 2. Side effects and noncompliance in patients treated with low- vs high-dose opioids for non-cancer pain (n = 182). Data are
presented as count (percentage).

Low-Dose
Opioid Group (n = 94)

Variable
Side Effects, n (%)
None

High-Dose
Opioid Group
(n = 88)

P Value†
.67

n = 94

n = 88

74 (78.7)

48 (54.5)
26 (29.5)

Constipation

15 (16)

Other

3 (3.2)

3 (3.4)

Constipation + other

2 (2.1)

11 (12.5)

Diagnoses, n (%)

n = 94

(n = 87)

Leg pain

8 (8.5)

9 (10.3)

Leg + Hip pain

1 (1.1)

0

5 (5.3)

4 (4.6)

Back pain

Hip pain (only)

53 (56.4)

51 (58.6)

Neck + Head pain

12 (12.8)

9 (10.3)

Peripheral pain

7 (7.4)

3 (3.4)

All other pain not falling into the above categories

8 (8.5)

11 (12.6)

.85

† A P value < .05 was considered statistically significant .

Table 3. Side effects and noncompliance in patients treated with low- vs high-dose opioids for non-cancer pain (n = 182). Data are
presented as count (percentage).

Variable

Low-Dose Opioid Group
(n = 94)

High-Dose Opioid Group
(n = 88)

P Value†

Side Effects, n (%)

20 (21.3)

40 (45.5)

.001*

Noncompliance, n (%)

31 (33.0)

43 (48.9)

.029*

† A P value < .05 was considered statistically significant .

medications were 1.94 times greater than the odds for a
low-dose opioid patient.
A total of 135 patients (74.2%) reported that they
were unemployed (not working) at the end of the
treatment period. Of these 135 patients, 129 provided
reasons for their unemployment. Responses were collapsed into one of 3 categories: disability, retirement,
and other. These categories included the most responses
and made the data more meaningful for analysis. There
was a statistically significant relationship between the
reported reason for unemployment and opioid treatment group (χ2[2] = 7.18, P =.03). Patients receiving
high-dose opioids were more likely to report “disability” as their reason for unemployment than patients
receiving low-dose opioids (55.4% vs 34.4%). Patients
receiving low-dose opioids were more likely to report
“retirement” as their reason for unemployment (37.7%
vs 20%). Table 3 summarizes this analysis (Table 4).
A total of 60 patients (33%) reported side effects

www.painphysicianjournal.com

during the treatment period. Of these 60 patients,
54 patients (90%) reported at least one complication
that included constipation. Eighty-five percent of patients receiving low-dose opioid treatment reported
at least one complication that included constipation,
compared with 92.5% of patients receiving high-dose
opioid treatment. There was no statistically significant
association between opioid treatment group and the
side-effect of constipation (P = .36).
The low- and high-dose opioid patients did not differ significantly on their own rating of their perceived
general health compared to one year earlier (49.2 ±
23.9 vs 52.8 ± 24.7, P = .31).
Table 5 summarizes the results of the SF-36 for each
of the 8 domains. There were no significant differences
between the low-dose and high-dose opioid treatment
groups on any of the mean scores from the 8 domains
of the SF-36. High-dose opioid patients scored higher
(an indication of less disability or better quality of life)
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Table 4. Reasons for unemployment in patients treated with low-dose vs high-dose opioids for non-cancer pain (n = 135) Data are
presented as count (percentage).

Low-Dose Opioid Group
(n = 94)

Variable
Reason for Unemployment†, n (%)

High-Dose Opioid Group
(n = 88)

P Value‡
.03*

(n = 55)

(n = 74)

Disability

21 (38.2)

41 (55.4)

Retired

23 (41.8)

15 (20.3)

Other

11 (20)

18 (24.3)

# Data are presented as count (percentage).
† Of the 61 patients in the low-dose opioid group who indicated that they were unemployed, only 55 patients provided a reason for their unemployment.
‡ A P value < .05 was considered statistically significant (*).

Table 5. Cronbach’s alpha and internal consistency for the 8 domains measured by the SF-36 in patients treated with low- vs high-dose
opioids for non-cancer pain (n = 182).

Low-Dose Opioid Group
(n = 94)
SF-36
Domain
Physical Functioning

Cronbach’s Alpha

Internal Consistency

(n = 82)
.894
(n = 90)

Role Limitations
-Emotional Health

(n = 91)

Vitality, Energy, or
Fatigue

(n = 90)

Emotional Well-Being

(n = 89)

Social Functioning

(n = 92)

.849

Pain

(n = 93)

General Health
Perceptions

Good

4

.848

Good

3

.876

Good

4

.850

Good

5

.622

Questionable

2

Good

2

Good

5

(n = 86)
Acceptable

(n = 89)
.802

.869

(n = 84)
Poor

.708

10

(n = 84)
Good

.533

Excellent

(n = 83)
Good

.852

.918

(n = 81)
Good

.826

# Items

Internal Consistency

(n = 83)
Good

.828

Cronbach’s Alpha
(n = 76)

Good

Role Limitations
-Physical Health

High-Dose Opioid Group
(n = 88)

.810
(n = 86)

Good

.818

Abbreviations: SF-36, 36-Item Short Form Health Survey.

Table 5a. Interpretation of Cronbach’s alpha

Cronbach's alpha

Internal Consistency Reliability

.9 ≤ α

Excellent

406

.8 ≤ α < .9

Good

.7 ≤ α < .8

Acceptable

.6 ≤ α < .7

Questionable

.5 ≤ α < .6

Poor

α < .5

Unacceptable

in only 2 domains, though not significantly: Role Limitations – Emotional, and Emotional Well-Being. In the
other 6 domains, low-dose opioid patients scored higher, though only General Health Perceptions approached
significance. The Physical Functioning domain had the
most missing responses (Table 6 and Fig. 2).
Mean scores on General Health Perceptions for
the low-dose and high-dose opioid groups were 50.3
± 21.6 and 44.4 ± 21.9, respectively (P = .07). Though
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Table 6. Mean scores for the 8 domains of the SF-36 in patients treated with low- vs high-dose opioids for non-cancer pain (n = 182)*

Variable
Physical Functioning

Low-Dose
Opioid Group (n = 94)

High-Dose
Opioid Group (n = 88)

P Value

(n = 82)

(n = 75)

Mean ± SD

41.2 ± 24.4

38.9 26.3

.56

Median (IQR)

35.0 (40.0)

40.0 (45.0)

.49

(n = 90)

(n = 83)

Mean ± SD

30.8 ± 37.7

25.0 36.0

.30

Median (IQR)

25.0 (50.0)

0 (50)

.20

(n = 91)

(n = 81)

Mean ± SD

45.4 ± 42.6

54.7 43.6

.16

Median (IQR)

33.3 (100)

66.7 (100)

.40

(n = 90)

(n = 83)

Role Limitations –Physical Health

Role Limitations – motional

Vitality, Energy, or Fatigue
Mean ± SD

40.7 ± 21.0

39.8 22.7

.79

Median (IQR)

42.5 (30.0)

45.0 (35.0)

.91

Emotional Well-Being

(n = 89)

(n = 84)

Mean ± SD

64.7 ± 21.7

67.0 21.7

.49

Median (IQR)

64.0 (38.0)

72.0 (28.0)

.40

Social Functioning

(n = 92)

(n = 85)

Mean ± SD

64.7 ± 24.0

63.4 26.4

.73

Median (IQR)

62.5 (37.5)

62.5 (37.5)

.95

(n = 93)

(n = 87)

Mean ± SD

33.2 ± 19.0

29.9 20.5

.26

Median (IQR)

32.5 (22.5)

22.5 (35.0)

.28

(n = 89)

(n = 86)

Pain

General Health Perceptions
Mean ± SD

50.3 ± 21.6

44.4 21.9

.07

Median (IQR)

50.0 (30.0)

42.5 (30.0)

.11

(n = 94)

(n = 88)

Health (Compared to Last Year)
Mean ± SD

49.2 ± 23.9

52.8 24.7

.31

Median (IQR)

50.0 (25.0)

50.0 (50.0)

.34

Abbreviations: IQR, interquartile range; SD, standard deviation; SF-36, 36-Item Short Form Health Survey.
* Higher scores are indicative of better health status. Data are presented as mean ± SD and median (25%-75% IQR). The SF-36 results are usually reported as mean ± SD; however, the distribution of many of the domains are nonnormal. P values are reported for each analysis method
(parametric vs nonparametric) showing that no significant values resulted from using either method. Some data are unavailable for each domain
analysis.
†A P value <0.05 was considered statistically significant

not reaching statistical significance, high-dose patients had lower item scores, indicating a perception
of poorer health. Figure 3 shows the mean scores for
General Health Perceptions in patients treated with
low- versus high-dose opioids for non-cancer pain. A
poststudy sample size calculation indicated that 106
patients would have been needed per group for the
difference found in this domain to reach statistical
significance.
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Cronbach’s alpha was used as a measure of internal
consistency (“reliability”) of the SF-36 questionnaire.
Internal consistency reliability describes the extent to
which all the items in a test measure the same concept
or construct; hence, it is connected to the interrelatedness of the items within the test. Cronbach’s alpha normally ranges between 0 and 1. The closer Cronbach’s
alpha coefficient is to 1.0, the greater the internal
consistency of the items in the scale (13). According to
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Fig. 2. Mean scores for the 8 domains of the SF-36 in patients treated with low- vs high-dose
opioids for non-cancer pain (n = 182).

Tavakol and Dennick, if a test has more than one concept, like the SF-36, it may
not make sense to report Cronbach’s alpha for the test as a whole, as the larger
number of questions will decidedly inflate the value of Cronbach’s alpha (14).
Tavakol and Dennick recommend reporting Cronbach’s alpha for each of the
domains separately rather than for the entire test.

Table 6 reports Cronbach’s
alpha for the 8 domains measured by the SF-36. Of the 8
domains of the SF-36, only
the Social Functioning domain
was considered unreliable; all
other domains had α > .70. The
Social Functioning domain,
which is based on 2 questions,
is a measure of limitations
in social activities because of
physical or emotional problems. The alpha coefficient for
the Social Functioning domain
was less reliable in the lowdose opioid treatment group
at .533 (n = 92) compared with
the alpha coefficient of .622 (n
= 84) in the high-dose group.

Discussion

Fig. 3. General health perceptions in patients treated with low- vs high-dose opioids for
non-cancer pain.
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There is increasing concern about the risks of and
negative side effects of opioid
medications. These concerns
are heightened for patients
who are prescribed high doses
of opioids. We examined the
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patients with CNCP who were prescribed daily opioid
doses of greater than 90 MME, relative to patients prescribed low-opioid doses, to attempt to better understand the social and functional implications of chronic
opioid treatment.
It was interesting to note that the patients receiving high-dose opioids tended to have a poorer perception of health as well as significantly increased reported
side effects, increased rates of unemployment, and
increased rates of noncompliance. Among the highdose opioid patients, disability was significantly more
likely to be listed as the reason for unemployment,
compared to retirement among patients receiving lowdose opioids. It is important to differentiate between
retirement and disability as the reason for a patient’s
unemployment. This is because if a patient retires, that
means the patient was able to voluntarily quit working.
On the other hand, if the reason is disability, it means
that the patient may have had to stop employment prematurely despite their desire to work, which may lead
to a lower quality of life. In addition, disability may underlie a more severe pathology or pain, as it restricted
them from working. It is not entirely clear whether or
not the high-dose opioid patients suffered from worse
pain or underlying pathology or functional impairment, but the 2 opioid treatment groups did not differ
significantly with respect to baseline characteristics of
age, BMI, gender, or 6 common categories of diagnosis.
The relationships between lower versus higher doses of
opioid treatment and level of pain reduction, amount
of functional improvement, as well as any improvement
in a patient’s physical and emotional health are complex and nonlinear. The results of this study indicate
that low-dose opioid patients tend to do significantly
better than high-dose opioid patients with respect to
fewer reported side effects, lower incidence of noncompliance, and higher rates of employment. Given
the significant risks of opioids – especially at higher dosages – including concerns about possible hyperalgesia,
and given no statistically significant improvements over
low-dose opioid treatment in regard to physical and
emotional health parameters, it is reasonable to conclude that high-dose opioid treatment for CNCP should
be avoided whenever possible.
There are some limitations to this study. First, its observational design prohibits drawing causal relationships
between the use of opioid treatment for non-cancer
pain and quality of life. Another limitation is that there
were restricted entry criteria into the study: chronic noncancer pain patients presenting at the West Penn Pain
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Institute between the ages of 18 to 80 who did not have
a concurrent cancer diagnosis and who were not receiving end-of-life care. Also, the study population was one
of convenience. The study population included patients
who were receiving opioid treatment at a single facility (large urban teaching hospital and Level 1 trauma
center), which may limit the generalizability of the
findings. Another limitation is that the SF-36 was only
given post-opioid treatment. The lack of a baseline SF-36
measure prevented us from quantitatively determining
how opioid treatment for non-cancer pain changed the
patients’ SF-36 scores post treatment.
Another limitation in this retrospective cohort
study is that it only provides a single snapshot view of
a patient’s perception of their current quality of life in
relation to their current pain regimen. In order to draw
conclusions about a patient’s change in quality of life,
we would need to collect more information about the
patient’s baseline level of pain or pathology, previous
perception about their quality of life, and previous
pain regimen. For instance, it could be that patients on
high-dose chronic opioid therapy have failed low-dose
therapy and have had to escalate to a higher dose.
Alternatively, it could be that patients on high-dose
opioid therapy may have had more severe pathology
or pain at the start of treatment. It would be interesting to do a longitudinal study incorporating the points
above to examine a temporal relationship between opioid dosage and quality of life. Also, patients enrolled in
the study had non-cancer pain associated with different conditions as well as different prognoses, thereby
raising the possibility of selection bias. Selection bias
can often result in patients having less favorable outcomes in one group compared to another group (15).
Self-reported data may not always be reliable. Cook
and Campbell have pointed out that subjects (a) choose
to report what they believe the researcher expects
to see; or (b) report what reflects them in a positive
light in terms of their abilities, knowledge, beliefs, or
opinions (16). Another concern about such data centers
on whether subjects are able to accurately recall past
behaviors.
A further drawback was the absence of data on
prior pain treatments, alcohol use, illegal drug use,
patient preference for treatment with low- versus highdose opioids, patient socioeconomic status, concurrent
benzodiazepine usage, psychiatric conditions, and education level. These variables may be factors affecting
the SF-36 scores of patients irrespective of their treatment of non-cancer pain with opioids. It would be in-
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teresting to look at treatment with benzodiazepines, in
particular, for future studies. Concurrent prescriptions
of benzodiazepines can be problematic, as sedativehypnotic medications may interact with opioids to increase the likelihood of adverse events, and non-opioid
pain medications are often recommended as one part
of a comprehensive pain management program to help
enhance pain control. It has been shown that polypharmacy with benzodiazepines may lead to higher risk of
aberrant behavior, adverse events including respiratory
depression, and overdose (17). Patients’ socioeconomic
status and concurrent psychiatric conditions would have
provided further insight as well. Low socioeconomic
status and psychiatric comorbidities may be predictive
of aberrant behaviors and are characteristics identified
in risk screening tools for prescribing opioids (18).

Conclusion
The SF-36 is a reliable measure of the physical and
emotional dimensions of health, specifically a patient’s
functional health, well-being, psychometrically-based
physical health, and mental health. The study also analyzed patients’ employment status, reasons for unemployment, pain diagnosis, side effects, and compliance
issues through the electronic medical record.
Data analysis suggests that low-dose and high-dose
opioid treatment patients do not have significantly different quality-of-life outcomes.
Patients receiving high-dose opioid treatment
tended to have a poorer perception of health as well
as significantly increased report of side effects, increased rates of unemployment, and increased rates of
noncompliance. Among the high-dose opioid patients,
disability was significantly more likely to be listed as
the reason for unemployment, as opposed to retire-
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ment for patients receiving low-dose opioids. Although
it is not entirely clear whether or not the high-dose
opioid patients suffered from worse pain or underlying
pathology or functional impairment, the 2 opioid treatment groups did not differ significantly with respect to
baseline characteristics of age, BMI, gender, or 6 common diagnosis categories.
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